Agilent companion diagnostic expands ce-ivd mark in europe to include esophageal cancer

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced that the company's pd-l1 ihc 22c3 pharmdx assay has expanded its use in europe. the assay is now ce-ivd marked for use as an aid in identifying esophageal cancer patients for treatment with keytruda using combined positive score (cps) ≥ 10.1 in europe, keytruda is approved in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with locally advanced unresectable or metastatic eso
A Ratings Summary
A Quant Ranking